These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2780939)

  • 21. T gamma cell levels in mammary and cervical uterine cancer patients before and after local irradiation treatment.
    Folch H; Armando S; Cardemil B; Eller G; Ojeda F
    Allergol Immunopathol (Madr); 1984; 12(5):383-6. PubMed ID: 6335357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer.
    Farquhar C; Basser R; Marjoribanks J; Lethaby A
    Cochrane Database Syst Rev; 2003; (1):CD003139. PubMed ID: 12535457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
    Chen Y; Chen K; Xiao X; Nie Y; Qu S; Gong C; Su F; Song E
    BMC Cancer; 2016 May; 16():320. PubMed ID: 27198767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of delayed initiation of adjuvant chemotherapy on breast cancer survival is subtype-dependent.
    Yu KD; Fan L; Qiu LX; Ling H; Jiang YZ; Shao ZM
    Oncotarget; 2017 Jul; 8(28):46549-46556. PubMed ID: 27447963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
    Adjuvant Breast Cancer Trials Collaborative Group
    J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma.
    Wood WC; Budman DR; Korzun AH; Cooper MR; Younger J; Hart RD; Moore A; Ellerton JA; Norton L; Ferree CR
    N Engl J Med; 1994 May; 330(18):1253-9. PubMed ID: 8080512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. National Institutes of Health Consensus Development Conference Statement: Adjuvant Chemotherapy for Breast Cancer. September 9-11, 1985.
    CA Cancer J Clin; 1986; 36(1):42-7. PubMed ID: 3080207
    [No Abstract]   [Full Text] [Related]  

  • 28. Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-up.
    Basser RL; To LB; Collins JP; Begley CG; Keefe D; Cebon J; Bashford J; Durrant S; Szer J; Kotasek D; Juttner CA; Russell I; Maher DW; Olver I; Sheridan WP; Fox RM; Green MD
    J Clin Oncol; 1999 Jan; 17(1):82-92. PubMed ID: 10458221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between immunological parameters and survival of patients with liver metastases from breast cancer given immuno-chemotherapy.
    Yamasaki S; Kan N; Harada T; Ichinose Y; Moriguchi Y; Li L; Sugie T; Kodama H; Satoh K; Ohgaki K
    Breast Cancer Res Treat; 1993; 26(1):55-65. PubMed ID: 8400324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined therapy for inflammatory breast cancer.
    Donegan WL; Padrta B
    Arch Surg; 1990 May; 125(5):578-82. PubMed ID: 2331213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B.
    Tross S; Herndon J; Korzun A; Kornblith AB; Cella DF; Holland JF; Raich P; Johnson A; Kiang DT; Perloff M; Norton L; Wood W; Holland JC
    J Natl Cancer Inst; 1996 May; 88(10):661-7. PubMed ID: 8627642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjustment to breast cancer: the psychobiological effects of psychosocial interventions.
    van der Pompe G; Antoni M; Visser A; Garssen B
    Patient Educ Couns; 1996 Jul; 28(2):209-19. PubMed ID: 8852096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer.
    Farquhar C; Marjoribanks J; Basser R; Lethaby A
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003139. PubMed ID: 16034886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF.
    Poikonen P; Saarto T; Lundin J; Joensuu H; Blomqvist C
    Br J Cancer; 1999 Aug; 80(11):1763-6. PubMed ID: 10468293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support.
    Rizzieri DA; Vredenburgh JJ; Jones R; Ross M; Shpall EJ; Hussein A; Broadwater G; Berry D; Petros WP; Gilbert C; Affronti ML; Coniglio D; Rubin P; Elkordy M; Long GD; Chao NJ; Peters WP
    J Clin Oncol; 1999 Oct; 17(10):3064-74. PubMed ID: 10506601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The dynamic change of neutrophil to lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
    Dan J; Tan J; Huang J; Zhang X; Guo Y; Huang Y; Yang J
    Breast Cancer; 2020 Sep; 27(5):982-988. PubMed ID: 32306184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy.
    Vredenburgh JJ; Madan B; Coniglio D; Ross M; Broadwater G; Niedzwiecki D; Edwards J; Marks L; Vandemark R; McDonald C; Affronti ML; Peters WP
    Bone Marrow Transplant; 2006 Jun; 37(11):1009-15. PubMed ID: 16633363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study.
    Falkson G; Holcroft C; Gelman RS; Tormey DC; Wolter JM; Cummings FJ
    J Clin Oncol; 1995 Jun; 13(6):1453-8. PubMed ID: 7751892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Initial therapeutic evaluations of 141 patients with carcinoma of the breast under 40 years of age].
    Cosentino D; Cazzaniga F; Scandolaro L; Marelli M; Sgro M; Clerici R; Gallosi D; Lattuada N; Sussi PL
    Chir Ital; 1984 Dec; 36(6):1014-25. PubMed ID: 6549578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group.
    Gelber RD; Goldhirsch A; Cavalli F
    Ann Intern Med; 1991 Apr; 114(8):621-8. PubMed ID: 2003707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.